肾癌卫星灶的研究进展

宋一萌; 周明新; 马潞林

doi:10.13201/j.issn.1001-1420.2019.02.019

肾癌卫星灶的研究进展

- 北京大学第三医院泌尿外科(北京, 100191)

详细信息

通讯作者: 马潞林,E-mail:malulin@medmail.com.cn

中图分类号: R737.11

收稿日期: 2017-12-13

Research progress of multifocal renal cell carcinoma

- Department of Urology, Peking University Third Hospital, Beijing, 100191, China

More Information

Corresponding author: MA Lulin, E-mail: malulin@medmail.com.cn

Received Date: 13 December 2017

摘要

摘要: 肾癌卫星灶通常指在同一侧肾内有同时存在2个或2个以上的肿瘤,无论这些肿瘤是否是同一组织类型或是否是同时发现的。卫星灶又称为多中心肾癌,是由多个小结节组成,且多由原发灶转移而来。多中心肾癌的发病机制和形成机制目前尚无定论。本文将总结近年多中心肾癌研究,对肾癌卫星灶发病原理作一综述。
- 肾癌卫星灶 /
- VHL基因 /
- FLCN基因 /
- 保留肾单位手术 /
- 肾内转移
Abstract: Multicentricity of renal cell carcinoma is the presence of two or more tumors in the same side of kidney, regardless of histology or timing of detection.Multifocal renal carcinoma consists of multiple small nodules.Almost of them metastasize from the primary tumors.It is not well known that how the renal carcinoma happen or develop.Thus, here we summarize the studies of multifocal renal carcinoma, with the aim of reviewing the etiopathogenesis of multifocal renal carcinoma.
- multicentricity of renal cell carcinoma /
- VHL /
- FLCN /
- nephron-sparing surgery /
- intrarenal metastasis

HTML全文

参考文献(37)

[1]	Sorbellini M, Bratslavsky G.Decreasing the indications for radical nephrectomy:a study of multifocal renal cell carcinoma[J].Front Oncol, 2012, 2:84.
[2]	Cairns P.Renal cell carcinoma[J].Cancer Biomark, 2010, 9 (1-6): 461-473.
[3]	Bratslavsky G, Linehan W M.Long-term management of bilateral, multifocal, recurrent renal carcinoma[J].Nat Rev Urol, 2010, 7 (5): 267-275.
[4]	Siracusano S, Novara G, Antonelli A, et al.Prognostic role of tumour multifocality in renal cell carcinoma[J].BJU Int, 2012, 110 (11b): E443-E448.
[5]	Dell'Atti L.Spontaneous rupture of the kidney affected by multifocal papillary renal cell carcinoma[J].Rare Tumors, 2014, 6 (4): 5568.
[6]	刘广华, 李汉忠, 夏溟, 等.多中心肾癌发生机制探讨[J].临床泌尿外科杂志, 2006, 21 (8): 579-581.
[7]	Richstone L, Scherr D S, Reuter V R, et al.Multifocal renal cortical tumors:frequency, associated clinicopathological features and impact on survival[J].J Urol, 2004, 171 (2Pt 1): 615-620.
[8]	王瑛, 范志强, 刘利敏, 等.肾癌多中心病灶的危险因素[J].临床医学工程, 2012, 19 (5): 774-775.
[9]	Tsivian M, Moreira D M, Caso J R, et al.Predicting Occult Multifocality of Renal Cell Carcinoma[J].Eur Urol, 2010, 58 (1): 118-126.
[10]	Byler T K, Bratslavsky G.Hereditary renal cell carcinoma:genetics, clinical features, and surgical considerations[J].World J Urol, 2014, 32 (3): 623-630.
[11]	Bausch B, Jilg C, Glasker S, et al.Renal cancer in von Hippel-Lindau disease and related syndromes[J].Nat Rev Nephrol, 2013, 9 (9): 529-538.
[12]	Linehan W M, Srinivasan R, Schmidt L S.The genetic basis of kidney cancer:a metabolic disease[J].Nat Rev Urol, 2010, 7 (5): 277-285.
[13]	Linehan W M.The genetic basis of kidney cancer:implications for management and use of targeted therapeutic approaches[J].Eur Urol, 2012, 61 (5): 896-898.
[14]	汪鑫, 胡骁轶, 王杭, 等.多灶性肾细胞癌24例临床分析[J].临床泌尿外科杂志, 2018, 33 (3): 212-216.
[15]	Park B K, Kim C K, Park S Y, et al.Percutaneous radiofrequency ablation of renal cell carcinomas in patients with von Hippel Lindau disease:indications, techniques, complications, and outcomes[J].Acta Radiol, 2013, 54 (4): 418-427.
[16]	Kaelin W J.The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma[J].Clin Cancer Res, 2007, 13 (2Pt 2): 680s-684s.
[17]	De Bels D, Corazza F, Balestra C.Oxygen sensing, homeostasis, and disease[J].N Engl J Med, 2011, 365 (19): 1845, 1846.
[18]	Maher E R, Neumann H P, Richard S.von Hippel-Lindau disease:a clinical and scientific review[J].Eur JHum Genet, 2011, 19 (6): 617-623.
[19]	Kondo K, Klco J, Nakamura E, et al.Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein[J].Cancer Cell, 2002, 1 (3): 237-246.
[20]	Essers P B, Klasson T D, Pereboom T C, et al.The von Hippel-Lindau tumor suppressor regulates programmed cell death 5-mediated degradation of Mdm2[J].Oncogene, 2015, 34 (6): 771-779.
[21]	Chen S, Sanford C A, Sun J, et al.VHL and PTEN loss coordinate to promote mouse liver vascular lesions[J].Angiogenesis, 2010, 13 (1): 59-69.
[22]	Zhou Q, Pardo A, Konigshoff M, et al.Role of von Hippel-Lindau protein in fibroblast proliferation and fibrosis[J].FASEB J, 2011, 25 (9): 3032-3044.
[23]	Yamada Y, Sakamoto S, Furuya M, et al.Case of bilateral and multifocal renal cell carcinoma associated with Birt-Hogg-Dube syndrome[J].Int J Urol, 2015, 22 (2): 230-231.
[24]	Schmidt L S, Linehan W M.Molecular genetics and clinical features of Birt-Hogg-Dube syndrome[J].Nat Rev Urol, 2015, 12 (10): 558-569.
[25]	Kassem L, Abdel-Rahman O.Targeting mTOR pathway in gynecological malignancies:Biological rationale and systematic review of published data[J].Crit Rev Oncol Hematol, 2016, 108:1-12.
[26]	Hasumi H, Baba M, Hasumi Y, et al.Regulation of mitochondrial oxidative metabolism by tumor suppressor FL-CN[J].J Natl Cancer Inst, 2012, 104 (22): 1750-1764.
[27]	Sargin S Y, Ekmekcioglu O, Arpali E, et al.Multifocality incidence and accompanying clinicopathological factors in renal cell carcinoma[J].Urol Int, 2009, 82 (3): 324-329.
[28]	Kongnyuy M, Lawindy S, Martinez D, et al.A Rare Case of the Simultaneous, Multifocal, Metastatic Renal Cell Carcinoma to the Ipsilateral Left Testes, Bladder, and Stomach[J].Case Rep Urol, 2016, 2016:1829025.
[29]	Junker K, Schlichter A, Hindermann W, et al.Genetic characterization of multifocal tumor growth in renal cell carcinoma[J].Kidney Int, 1999, 56 (4): 1291-1294.
[30]	Schlichter A, Fiedler W, Junker K, et al.Determination of telomerase activity in multifocal renal cell carcinoma[J].Int J Oncol, 1999, 15 (3): 577-581.
[31]	Ljungberg B, Bensalah K, Canfield S, et al.EAU guidelines on renal cell carcinoma:2014update[J].Eur Urol, 2015, 67 (5): 913-924.
[32]	Venkatramani V, Swain S, Satyanarayana R, et al.Current Status of Nephron-Sparing Surgery (NSS) in the Management of Renal Tumours[J].Indian J Surg Oncol, 2017, 8 (2): 150-155.
[33]	Uzzo R G, Novick A C.Nephron sparing surgery for renal tumors:indications, techniques and outcomes[J].JUrol, 2001, 166 (1): 6-18.
[34]	Metwalli A R, Linehan W M.Nephron-sparing surgery for multifocal and hereditary renal tumors[J].Curr Opin Urol, 2014, 24 (5): 466-473.
[35]	Zargar-Shoshtari K, Kim T, Simon R, et al.Surveillance Following Nephron-Sparing Surgery:An Assessment of Recurrence Patterns and Surveillance Costs[J].Urology, 2015, 86 (2): 321-326.
[36]	Lopez-Costea M A, Bonet X, Perez-Reggeti J, et al.Oncological outcomes and prognostic factors after nephron-sparing surgery in renal cell carcinoma[J].Int Urol Nephrol, 2016, 48 (5): 681-686.
[37]	Borghesi M, Brunocilla E, Schiavina R, et al.Positive surgical margins after nephron-sparing surgery for renal cell carcinoma:incidence, clinical impact, and management[J].Clin Genitourin Cancer, 2013, 11 (1): 5-9.